55results about How to "Good neutralizing activity" patented technology

The invention discloses a hybridoma cell strain and an anti-porcine-epidemic-diarrhea-virus monoclonal antibody produced by the hybridoma cell strain. The anti-porcine-epidemic-diarrhea-virus monoclonal antibody has the preventing and/or treating function for porcine epidemic diarrhea viruses, solves the problem of piglet epidemic diarrhea virus infection caused when existing vaccines and maternal antibodies are insufficient, overcomes the defect that an existing vaccine is single in prevention function and can also be used for developing diagnostic reagent products for the porcine epidemic diarrhea viruses.

The invention relates to an anti-H7N9 full-human-derived monoclonal antibody 5J13 and a preparation method and application thereof. Amino acid sequences of heavy and light chain CDR1, CDR2 and CDR3 of the antibody are GFSFSNYG in the heavy chain CDR1 area, ISYDGTNK in the heavy chain CDR2 area, AKGRGPYCSSSICYHGMDV in the heavy chain CDR3 area, QSVLSGSINMNY in the light chain CDR1 area, WAS in the light chain CDR2 area and QQYYSTPLT in the light chain CDR3 area correspondingly. The antibody can be combined with hemagglutinin A of the H7N9virus in a targeted mode and has remarkable neutralization activity in resisting H7N9 virus infection. Compared with a murine antibody, genes of the full-human-derived antibody are completely from human genes and have no components of other species, toxic and side effects such as the anti-mouse anti-antibody are avoided, the biocompatibility is better, and the anti-H7N9 full-human-derived monoclonal antibody 5J13 is more suitable and has more potential in becoming a macromolecular drug for treating influenza virus.

The invention discloses a method for preparing a recombinant human papillomavirus 16-typed L1 protein with a pichia pastoris expression system and comprises the steps of loading an HPV 16 L1 gene in accordance with optimal design into an expression carrier, transforming pichia pastoris and cultivating a transformant, thus obtaining the recombinant human papillomavirus 16-typed L1 protein, which is self-assembled into virus-like particles inside a pichia pastoris body; wherein, nucleotide sequences of the HPV 16 L1 gene in accordance with optimal design are shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3. The HPV 16 L1protein that is prepared by the method of the invention has high expressed quantity. The invention further discloses a method for preparing a papillomavirus 16-typed infection vaccine with better activity by utilizing the virus-like particles of the recombinant HPV 16 L1 protein.

The invention discloses a method for preparing a recombinant human papillomavirus 18-typed L1 protein with a pichia pastoris expression system and comprises the steps of loading an HPV 18 L1 gene in accordance with optimal design into an expression carrier, transforming pichia pastoris and cultivating a transformant, thus obtaining the recombinant human papillomavirus 18-typed L1 protein, which is self-assembled into virus-like particles inside a pichia pastoris body; wherein, nucleotide sequences of the HPV 18 L1 gene in accordance with optimal design are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 or SEQ ID NO.6. The HPV 18 L1protein that is prepared by the method of the invention has high expressed quantity. The invention further discloses a method for preparing a papillomavirus 18-typed infection vaccine with better activity by utilizing the virus-like particles of the recombinant HPV 18 L1 protein.

The application relates to an anti-H7N9 full human derived monoclonal antibody hIg311 and a preparation method and application thereof. A memory B cell PCR method is used for quickly screening a fullhuman derived monoclonal antibody hIg311, and the anti-H7N9 human derived monoclonal antibody hIg311 is free from any mouse derived components. The antibody disclosed by the application can realize target combination of hemagglutinin HA of H7N9 viruses, and has notable anti H7N9 viral infection neutralization activity. The antibody disclosed by the application does not generate toxic and side effects for resisting mouse resisting antibodies, has good biocompatibility, and is suitable for becoming and has potential to become macromolecular drugs for treating influenza viruses.

The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.

The invention discloses a human-mouse chimeric anti-CXCR2 full-molecule IgG and an application thereof and belongs to the field of biological pharmacy. The human-mouse chimeric anti-CXCR2 full-molecule IgG comprises a heavy chain variable region and a light chain variable region and is characterized in that the light chain variable region has a nucleic acid sequence shown in the formula of SEQ IDNO. 1 and the heavy chain variable region has a nucleic acid sequence shown in the formula of SEQ ID NO. 2. The mouse immunized by the specific recombinant CXCR2 protein is used, a mouse-derived anti-CXCR2 monoclonal antibody is prepared through a hybridoma technology, and the recombinant human-mouse chimeric anti-CXCR2 full-molecule IgG is prepared through genetic engineering and antibody engineering techniques. The chimeric antibody can effectively recognize the CXCR2 extracellular domain amino acid fragment and inhibit the binding of the CXCR2 protein to the GRO alpha protein.

The invention provides an anti-filovirus monoclonal neutralizing antibody as well as a preparation method and application thereof. A heavy chain variable region of an antigen binding segment of the monoclonal neutralizing antibody comprises amino acid sequences of SEQ ID NO:13 or SEQ ID NO:15 shown in the specification, and a light chain variable region of the antigen binding segment of the monoclonal neutralizing antibody comprises amino acid sequences of SEQ ID NO:14 or SEQ ID NO:16 shown in the specification. The antigen binding segment of the monoclonal neutralizing antibody is obtained from adult Chinese rhesus monkeys, after humanization, the antibody has good neutralizing activity upon three pseudoviruses of a Zaire type, a Sultan type and a Marburg type of filovirus, and has good affinity upon GP (glycoprotein); and the monoclonal neutralizing antibody is potentially applied to research on anti-filovirus treatment medicines, research on anti-filovirus detection kits, molecularbiological reagents for anti-filovirus antigen detection, and the like.

The invention discloses a neutralizing monoclonal antibody against Ebola virus. Specifically, the invention discloses a monoclonal antibody against Ebola virus. The antibody has significant binding activity to Ebola virus antigen, and Has cross-neutralizing activity against Zaire and Sudan subtypes.

The invention discloses an anti-coronavirus bispecific neutralizing antibody and application thereof. Specifically, the invention discloses a bispecific antibody specifically combined with different epitopes of a novel coronavirus S protein receptor binding domain and application thereof. The bispecific antibody comprises a single-chain antibody SFC3scFv and a complete humanized antibody HSA-1F structure, has a highly stable symmetric structure, shows better neutralizing activity compared with a parent antibody and when the bispecific antibody is combined with the parent antibody, and also shows better neutralizing activity on an SARS-CoV-2 variant strain, an SARS-CoV virus and an MERS-CoV virus. According to the bispecific antibody, the neutralizing effect of the novel coronavirus is remarkably improved, the probability of generation of virus escape mutation is reduced, the treatment and prevention means of COVID-19 are enriched, and the bispecific antibody has a huge prospect of becoming a broad-spectrum antibody drug aiming at the coronavirus and has important significance on prevention and treatment of coronavirus infection.

The invention provides a canine parvovirus resistant genetic engineering antibody and an application thereof, and relates to the technical field of antibody engineering. A variable region sequence ofan acquired canine parvovirus monoclonal antibody is assembled with a canine antibody constant region to obtain the canine parvovirus resistant genetic engineering chimeric antibody, according to experimental verification, the hemagglutination inhibition titer of cell supernatant of the genetic engineering antibody is 1:(24-25), and the neutralizing titer of the cell supernatant is 1:203. Obviously, the genetic engineering antibody shows good canine parvovirus neutralizing activity, agglutination of red blood cells by canine parvoviruses can be inhibited, and the canine parvovirus resistant genetic engineering antibody can be applied to the field of canine research of the monoclonal antibody, canine parvovirus control and the like, and is of great significance for promoting development ofcanine monoclonal antibody drugs.

The application relates to an anti-H7N9 fully humanized monoclonal antibody 4E18 and a preparation method therefor and application of the humanized monoclonal antibody. The fully humanized monoclonalantibody 4E18 is quickly screened from memory B cells by utilizing a polymerase chain reaction (PCR) method, and does not contain any murine component. The antibody of the application can be bound tohemagglutinin (HA) of an H7N9 virus in a targeted manner, and has a neutralizing activity of significantly resisting H7N9 virus infection; the antibody of the application does not have an anti-mouse anti-antibody toxic and side effect and the like, has higher biocompatibility, and is more suitable and has more potential to become a macromolecular drug for treating influenza viruses.

The invention discloses an SARS-CoV-2 Spike protein receptor binding domain dimer and an application thereof, and particularly relates to an SARS-CoV-2 RBD dimer (SARS-CoV-2 RBD dimer) or an SARS-CoV-2 RBD monomer (SARS-CoV-2 RBD monomer) and an application of the SARS-CoV-2 RBD dimer or the SARS-CoV-2 RBD monomer or the SARS-CoV-2 RBD monomer or the SARS-CoV-2 RBD monomer or the SARS-CoV-2 RBD monomer in neutralizing the SARS-CoV-2, and the SARS-CoV-2 RBD dimer or the SARS-CoV-2 RBD monomer in neutralizing the SARS- the invention provides a dimer of SARS-CoV-2 RBD, and a preparation method of the dimer, a protein represented by Sequence 1 in the sequence table, a protein represented by Sequence 3 in the sequence table, and the protein shown as the 34th-272th amino acid residues in the sequence 3 of the sequence table. The invention has important value and wide application prospect in research and development of drugs, vaccines and the like for treating and preventing SARS-CoV-2.

The application relates to an anti-H7N9 fully humanized monoclonal antibody 2G3 and a preparation method therefor and application of the humanized monoclonal antibody. The fully humanized monoclonal antibody 2G3 is quickly screened from memory B cells by utilizing a polymerase chain reaction (PCR) method, and does not contain any murine component. The antibody of the application can be bound to hemagglutinin HA of an H7N9 virus in a targeted manner, and has a neutralizing activity of significantly resisting H7N9 virus infection; the antibody of the application does not have an anti-mouse anti-antibody toxic and side effect and the like, has higher biocompatibility, and is more suitable and has more potential to become a macromolecular drug for treating influenza viruses.

The invention relates to an anti-H7N9 full-human monoclonal antibody 3F12 as well as a preparation method and application thereof. The full-human monoclonal antibody 3F12 is rapidly screened by usinga memory B cell PCR (polymerase chain reaction) method, and no mouse-derived component is involved. The antibody provided by the invention is capable of achieving targeted combination with hemagglutinin HA of an H7N9 virus, and has remarkable anti-H7N9 virus infection neutralization activity. The antibody provided by the invention is free of toxic and side effect such as anti-mouse antiantibodies,has good biocompatibility and is suitable for and has the potential of being used as macromolecule medicines for treating influenza viruses.

The invention relates to an anti-H7N9 whole-human monoclonal antibody 7T33 and a preparation method therefor and application of the anti-H7N9 whole-human monoclonal antibody 7T33. The whole-human monoclonal antibody 7T33 is quickly screened by utilizing a memory B cell polymerase chain reaction (PCR) method, and does not include any murine component. The antibody disclosed by the invention can bebound to hemagglutinin HA of an H7N9 virus in a targeted manner, and has significant neutralizing activity of anti-H7N9 virus infection; and the antibody disclosed by the invention does not have toxicand side effects of anti-mouse anti-antibodies and the like, has better biocompatibility, and is more suitable and has more potential to become a macromolecular drug for treatment of influenza viruses.

The invention provides a preparation method and application of a nanoparticle for showing a hepatitis C virus envelope protein E2. Specifically, a truncated envelope protein sE2 (384-661) gene of an HCV 1B-type Con1 strain and a helicobacter pylori nonheme-iron protein gene are subjected to fusion expression, and sE2 can be shown on the surface of a nanoparticle in a correct conformation by self-assembling of ferroprotein monomers, so that the nanoparticle can be prepared into an HCV nanoparticle vaccine with good antigenicity and high safety, and the immunogenicity of a fusion protein is remarkably improved.